Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab and Bortezomib in Untreated Waldenstrom Macroglobulinemia
NCT01536067Phase 2Terminated
- Sponsor
- Roswell Park Comprehensive Cancer Center
- Start
- Apr 2012
- Primary completion
- Apr 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ofatumumab in Waldenstrom macroglobulinemia (WM), sponsored by Roswell Park Comprehensive Cancer Center. Started Apr 2012; status: terminated.
02
Drugs
ofatumumab
03
Conditions
Waldenstrom macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT01536067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01536067.